Reply to: Successful Isatuximab Desensitization in a Patient With Refractory Multiple Myeloma and Indolent Systemic Mastocytosis
- 26 January 2024
- journal article
- letter
- Published by Esmon Publicidad, SA in Journal of Investigational Allergology and Clinical Immunology
- Vol. 34 (3) , 216-217
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Successful Desensitization to Isatuximab in a Patient With Refractory Multiple Myeloma and Indolent Systemic Mastocytosis Reply to: Anaphylactic Shock due to Isatuximab and Successful DesensitizationJournal of Investigational Allergology and Clinical Immunology, 2024
- Flow‐based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paperAllergy, 2023
- Anaphylactic shock due to isatuximab and successful desensitizationJournal of Investigational Allergology and Clinical Immunology, 2023